

Medical benefit specialty drug update bulletin – November 2024

Specialty drug program updates for UnitedHealthcare Commercial, Community Plan, Medicare Advantage and Individual & Family Plans

| Specialty medical injectable drugs added to Review at Launch | | | | | | | |
|---|-----------------------|--------------------------------|------------------------------------|--|---|--|--|
| Drug Name | HCPCs Code(s) | UnitedHealthcare Commercial | UnitedHealthcare Community Plan | UnitedHealthcare Medicare Advantage | UnitedHealthcare Individual & Family | | |
| Jubbonti® (denosumab-bbdz) Biosimilar to Prolia® | Q5136 | | | Х | | | |
| Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq) | J3490/J3590/ C9399 | | | Х | | | |
| Wyost [®] (denosumab-bbdz) <i>Biosimilar to Xgeva</i> [®] | Q5136 | | | Х | | | |



Note: Drugs added to Review at Launch may not yet be available in the marketplace.

To view the **UnitedHealthcare Commercial Plan** Review at Launch Medication List, visit <u>UHCprovider.com</u> > Resources > Health plans, policies, protocols and guides > For Commercial Plans > Medical & Drug Policies for UnitedHealthcare Commercial Plans > Review at Launch for New to Market Medications – Commercial Medical Benefit Drug Policy > Review at Launch Medication List.

To view the **UnitedHealthcare Community Plan** Review at Launch Drug List Plan, visit <u>UHCprovider.com</u> > Resources > Health plans, policies, protocols and guides > For Community Plans > Medical & Drug Policies for Community Plan > Review at Launch for New to Market Medications – Community Plan Medical Benefit Drug Policy > Review at Launch Medication List.





For **UnitedHealthcare Medicare Advantage**, Review at Launch drugs are added as Review at Launch Part B Medications in the *Medications/Drugs* (Outpatient/Part B) Coverage Summary. To view the summary, visit <u>UHCprovider.com</u> > Resources > Health plans, policies, protocols and guides > For Medicare Advantage Plans > Supporting Information > Other Examples of Specific Drugs/Medications.

To view the **UnitedHealthcare Individual & Family Plan** Review at Launch Medication List, visit <u>UHCprovider.com</u> > Resources > Health plans, policies, protocols and guides > For Individual Exchange Plans > Medical & Drug Policies for UnitedHealthcare Individual Exchange Plans > Review at Launch for New to Market Medications – Individual Exchange Medical Benefit Drug Policy > Review at Launch Medication List.

| Updates to drug program requirements and drug policies | | | | | | | |
|--|-------------------|--------------------------------|------------------------------------|--|---|---|--|
| Drug Name | Effective Date | UnitedHealthcare Commercial | UnitedHealthcare Community Plan | UnitedHealthcare Medicare Advantage | UnitedHealthcare Individual & Family | Summary of Changes | |
| Monoferric® (ferric derisomaltose) | 2/1/25 | | X Indiana only | | | Add prior authorization/ notification | |
| Tremfya [®] IV (guselkumab) | 2/1/25 | Х | Х | Х | X | Add prior authorization/ notification Add to site of care for Commercial and Community Plans | |

Upon prior authorization renewal, the updated policy will apply. UnitedHealthcare will honor all approved prior authorizations on file until the end date on the authorization or the date the member's eligibility changes. You don't need to submit a new notification/prior authorization request for members who already have an authorization for these medications on the effective date noted above.

Note: Certain specialty medical injectable drug programs and updates will not be implemented at this time for providers practicing in Rhode Island, with respect to certain commercial members, pursuant to the Rhode Island regulation: 230 -RICR-20-30-14. UnitedHealthcare encourages providers practicing in Rhode Island to call in to confirm if prior authorization is required. This exception does not apply to Medicaid and Medicare.

| Specialty medical injectable drugs added to Medication Sourcing for Outpatient Hospital Providers Only – UnitedHealthcare Commercial | | | | | | | |
|--|----------------|---------------|--------------------|--|--|--|--|
| Drug Name | Effective Date | HCPCs Code(s) | Specialty Pharmacy | | | | |
| Tremfya IV (guselkumab) | 2/1/25 | J1628 | TBD | | | | |





Outpatient hospitals are required to obtain the medications listed in the Medication Sourcing Protocol - Requirements to use a participating specialty pharmacy for certain medications document from the indicated specialty pharmacies for distribution of these medications, unless otherwise authorized by us. When the specialty medication is obtained through the specialty pharmacy, the specialty pharmacy will bill us directly for these medications under the member's medical benefit. The facility administering the specialty drug is not to bill us for the medication obtained through the specialty pharmacy but may bill us for the administration of the medication to the member.

